GLP-1 Receptor Agonists Decrease the Rate of Rupture, Cardiac Events, and Death in Patients with Abdominal Aortic Aneurysms.
GLP-1 drugs were linked to fewer aortic aneurysm ruptures, heart attacks, and deaths over five years in a large matched study.
This retrospective propensity-matched cohort study examined glp-1 receptor agonists decrease the rate of rupture, cardiac events, and death in patients with abdominal aortic aneurysms. The PubMed abstract reports in 13,722 matched patients per group, glp-1 receptor agonist use was associated with fewer abdominal aortic aneurysm ruptures, major cardiovascular events, and deaths over five years.
What the study was
- Study design
- Retrospective propensity-matched cohort study
- Population
- Patients with abdominal aortic aneurysm under imaging surveillance
- Sample size
- 13722
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Journal of vascular surgery
Why it surfaced
Score reflects the retrospective propensity-matched cohort study design and relevance to Cardiovascular-metabolic: GLP-1, SGLT2, cardiometabolic risk; classification is limited to PubMed title, metadata, and abstract evidence.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.